Lineage Cell Therapeutics Achieves $5 Million Milestone Payment Under Roche Agreement
Lineage Cell Therapeutics Inc. has achieved a $5 million milestone payment under its collaboration with Genentech and Roche for the OpRegen cell therapy program. This payment, based on manufacturing and clinical advancements, will be received within 30 days. Portions of the payment will be allocated to the Israel Innovation Authority and Hadasit Medical Research, as per existing agreements. OpRegen is in a Phase 2a trial for treating geographic atrophy due to age-related macular degeneration.
Lineage Cell Therapeutics Inc. announced the achievement of the first development milestone under its collaboration and license agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. related to the OpRegen cell therapy program. This milestone, based on manufacturing and clinical advancements, triggered a $5 million milestone payment to Lineage, expected to be received within 30 days. Approximately 24.1% of the payment will be allocated to the Israel Innovation Authority and 21.5% to Hadasit Medical Research and Development Ltd., in accordance with existing agreements and regulations. OpRegen is currently in a Phase 2a clinical trial for the treatment of geographic atrophy secondary to age-related macular degeneration. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-291979), on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
